Trial Profile
Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Rivoceranib (Primary)
- Indications Adenocarcinoma; Lung cancer
- Focus Therapeutic Use
- 14 Mar 2016 New trial record